AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 271 min read$UTHR

ROTHBLATT MARTINE A sold $5.6M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $588.64 ($585.71–$592.92, $5.59M total) across 8 trades on 2026-10-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Oct 27, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Bearish
medium confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRBearishLow
01

Why it matters

The transaction reduces the CEO's ownership to 324,443 shares, a modest decline that may be interpreted by investors as a signal.

02

Market read

Insider sales are closely watched; this filing provides fresh data for traders evaluating short‑term sentiment on UTHR.

03

What to watch

Potential upcoming clinical data releases that may offset short‑term selling pressure.

Relevance 5/10Novelty 7/10Timing: post‑market today

Background

Form 4 filing discloses insider transactions required by the SEC; this is the first public disclosure of the sale.

Company-level read

Ticker impact

$UTHRBearishMedium confidence
Context

CEO Martine Rothblatt sold $5.6M of United Therapeutics shares via a 10b5-1 plan on 2026-10-26.

Expected impact

likely downward pressure as the market prices in the insider sell.

Evidence & confidence

A $5.6M sale by the chairperson is material for a mid‑cap biotech; such transactions often lead to modest price dips.

Market effects

Sector

Minimal; the sale does not affect the broader biotech sector.

Regional

None; impact confined to United Therapeutics shareholders.

Global

Low; no broader market ripple expected.

Counterpoint

What could challenge this read

The sale could be routine under a 10b5‑1 plan and not indicative of fundamental concerns.

Key entities

  • company
    United Therapeutics Corp

    Biopharmaceutical company developing organ transplant therapies.

  • person
    Martine A. Rothblatt

    Chairperson & CEO of United Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

OCT 28
$UTHRMed

United Therapeutics Receives FDA Clearance to Begin Clinical Trial of Inhaled PAH Treatment

United Therapeutics (UTHR) received FDA clearance to start clinical trials for Treprostinil-Iloprost SMI, an inhaled treatment for pulmonary arterial hypertension (PAH). The phase 1 trial will assess safety and tolerability. The therapy aims to address symptom flare-ups between maintenance doses. UTHR plans a phase 2 trial in 2027 if initial results are positive. PAH affects around 500,000 people globally.

finance.yahoo.com2 min
OCT 28
$UTHRMed

FDA clears a trial of a two-drug inhaler that could be the first as-needed therapy for lung artery disease.

The FDA approved a trial for Treprostinil-Iloprost SMI, a potential first as-needed inhaler therapy for pulmonary arterial hypertension (PAH). United Therapeutics plans a phase 1 study in 2026, with a phase 2 study in PAH patients anticipated in 2027. The therapy combines treprostinil and iloprost, aiming to provide episodic symptom relief. United Therapeutics aims to expand its PAH treatment portfolio.

stocktitan.net2 min